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Introduction {#sec007}
============

Intimate partner violence (IPV) against women is a major public health problem. It is the most common form of violence experienced by women and includes physical, sexual, and emotional abuse and controlling behaviors by an intimate partner \[[@pmed.1002995.ref001]\]. Estimates of the prevalence of IPV against women vary widely depending on the definitions. Worldwide, around 30% of women have experienced physical or sexual violence by their current or previous intimate partner \[[@pmed.1002995.ref002]\]. IPV is associated with a wide range of serious health consequences in victims, such as physical injuries, pregnancy termination, sexually transmitted diseases, post-traumatic stress disorder, depression, and suicidality \[[@pmed.1002995.ref003]--[@pmed.1002995.ref007]\]. In addition, children exposed to IPV often develop a wide range of physical health, mental health, and social adjustment problems \[[@pmed.1002995.ref008]\].

One potential risk factor for perpetrating IPV against women is mental illness, and etiological links may differ between different disorders. Common deficits associated with mental disorders, such as poor interpersonal skills and emotional dysregulation \[[@pmed.1002995.ref009],[@pmed.1002995.ref010]\], and specific core symptoms of certain disorders---such as impulsivity manifested in individuals with attention deficit hyperactivity disorder (ADHD) and substance use disorders \[[@pmed.1002995.ref011],[@pmed.1002995.ref012]\] and hostility exhibited in some people with mood disorders and antisocial personality disorder \[[@pmed.1002995.ref013]--[@pmed.1002995.ref015]\]---have been linked to IPV against women \[[@pmed.1002995.ref015],[@pmed.1002995.ref016]\]. Preliminary evidence suggests that individuals with mental illness have increased risk of perpetrating IPV against women \[[@pmed.1002995.ref017],[@pmed.1002995.ref018]\]. Systematic reviews have reported an increased risk of IPV perpetration among individuals with a range of mental disorders including depression, anxiety disorders, panic disorders, substance use disorders, and personality disorders, particularly antisocial personality disorder and borderline personality disorder \[[@pmed.1002995.ref019]--[@pmed.1002995.ref022]\]. However, the majority of existing empirical studies have been conducted with small sample sizes, have been based on selected samples, have relied on self-report of risk factors and outcomes, and, most importantly, have lacked adequate adjustment of confounders such as familial factors. There is considerable imprecision in previous work, partly due to different methodologies and samples. For instance, the hazard ratio of physical violence against a partner by men has ranged from 1.7 to 5.5 for depression and from 0.8 to 9.1 for anxiety disorder \[[@pmed.1002995.ref020]\].

Most of the evidence to date suggests some associations between mental disorders and IPV against women, but these associations might reflect underlying confounders or reverse direction of effects. Thus, the magnitude and direction of the links between mental disorders and IPV perpetration need clarification. In addition, the evidence for some disorders is very limited, particularly for specific psychiatric disorders, including schizophrenia-spectrum disorders, and developmental disorders such as ADHD and autism. For instance, autism, which is characterized by abnormal development of communication and social interaction \[[@pmed.1002995.ref023]\], has been proposed to be associated with IPV as a result of impaired theory of mind, poor emotional regulation, and problems with moral reasoning \[[@pmed.1002995.ref024]\]. In addition, health services research has suggested that it is especially difficult to help men with autism due to their inability to appreciate their partner's perspective, especially when arguments occur. Furthermore, the role of common psychiatric comorbidities, such as substance use disorders and personality disorders, is unclear.

Clarifying these associations can assist in developing more effective prevention and intervention programs \[[@pmed.1002995.ref025]\]. To date, many such programs targeting perpetrators of IPV typically have limited effectiveness \[[@pmed.1002995.ref026]\], and this may be partly related to the lack of modifiable factors in these programs.

Therefore, the aim of this study is to address these uncertainties in the association between mental disorders and men's IPV against women. To this end, we investigated risk of IPV against women among men with mental disorders in a population-based longitudinal cohort. As familial factors, such as genetic predisposition and shared childhood adversity, are associated with both mental disorders and IPV perpetration \[[@pmed.1002995.ref027]\], we conducted sibling comparisons to control for familial confounders, and we also conducted a range of sensitivity analyses to identify potential moderators. To our knowledge, this is the largest epidemiological study of IPV perpetrators to date and the first to use sibling comparisons.

Methods {#sec008}
=======

Study population and design {#sec009}
---------------------------

We used the unique 10-digit personal identification number \[[@pmed.1002995.ref028]\] assigned to each Swedish resident to link several national registers in Sweden: the National Patient Register \[[@pmed.1002995.ref029]\], the National Crime Register, the Multi-Generation Register (Statistics Sweden) \[[@pmed.1002995.ref029]\], and the Longitudinal Integration Database for Health Insurance and Labour Market Studies.

We selected a cohort of individuals born between 1 January 1958 and 31 December 1998, who were followed from 1 January 1998 to the end of follow-up on 31 December 2013. We started our follow-up on 1 January 1998 as records of IPV perpetration in the National Crime Register started at that time. In this study, we focused only on IPV perpetrated by men towards women, which is recorded as a separate category of crime in the crime register. We could not examine IPV perpetrated by women towards men as current data in the Swedish registers do not separate this type of crime from general domestic violence in women. Arrests for male-to-female IPV were retrieved from the National Crime Register using a distinct crime code (0412), which is a unique advantage over crime data from many other countries where such a code is absent. The project was approved by the Regional Ethics Review Board in Stockholm, Sweden (2013/5:8), which waived the need for informed consent as anonymized register-based data were used.

Mental disorder classifications {#sec010}
-------------------------------

We studied 9 psychiatric disorders diagnosed in either an inpatient or outpatient setting between 1998 and 2013: schizophrenia-spectrum disorders, bipolar disorder, depressive disorder, anxiety disorder, alcohol use disorder, drug use disorder, ADHD, autism, and personality disorders. These disorders were classified according to ICD-10, using the following codes: schizophrenia-spectrum disorders (F20--F29), bipolar disorder (F30, F31), depressive disorder (F32--F39), anxiety disorder (F40--F42, F44--F45, F48), alcohol use disorder (F10 except x.5), drug use disorder (F11--F19 except x.5), ADHD (F90), autism (F84.0, F84.1), and personality disorders (F60). We adopted a hierarchical approach to the following diagnoses: schizophrenia-spectrum disorders, bipolar disorder, depressive disorder, and anxiety disorder, as research has shown that some diagnoses change over time (to a more stable one). For instance, depression and anxiety can be precursors of schizophrenia-spectrum disorders \[[@pmed.1002995.ref030],[@pmed.1002995.ref031]\]. Thus, individuals with any diagnosis of bipolar disorder but not schizophrenia-spectrum disorder were regarded as having bipolar disorder. Individuals with any diagnosis of depressive disorder but neither schizophrenia-spectrum disorder nor bipolar disorder were regarded as having depressive disorder. Individuals with any diagnosis of anxiety disorder but without schizophrenia-spectrum disorder, bipolar disorder, and depressive disorder were considered as having anxiety disorder. This approach is expected to increase the validity of the above-mentioned mental disorders but could risk potentially underestimating some comorbidities. Therefore, we included comorbidities for common disorders including substance use disorders and personality disorders in the sensitivity analyses (see the statistical analyses section below). For diagnoses of alcohol use disorder, drug use disorder, ADHD, autism, and personality disorders, no hierarchical approach was assigned. Therefore, these disorders included both primary and secondary diagnoses. Diagnoses identified before arrest for IPV during 1998--2013 were defined as the exposure in this study. Swedish register-based psychiatric diagnoses generally have moderate to high concordance rates with clinical diagnoses \[[@pmed.1002995.ref029]\].

Outcome measure {#sec011}
---------------

Data for arrests for IPV between 1 January 1998 and 31 December 2013 were retrieved for all individuals in the cohort from the National Crime Register. This register includes crime data for all individuals aged 15 years (the age of criminal responsibility) and older. As a minority of IPV arrests result in conviction \[[@pmed.1002995.ref032]\], we used first IPV arrest after diagnosis as our primary outcome. IPV against women is defined as threats, violence, and sexual assaults where the victim is a woman and the current or ex-partner is the offender (criminal code: 0412). In a sensitivity analysis, we included general domestic violence as the outcome, defined as violence against a person that the offender has or has had a close relationship to, including partners, children, parents, and siblings of the offender (criminal codes: 0411, 0412, 0422, 0423, 0424, 0425, 0440, 0441, 0442, and 0443). The National Crime Register has 99% coverage of the population \[[@pmed.1002995.ref033]\].

Sociodemographic covariates {#sec012}
---------------------------

We collected information on the following covariates: family disposable income, single status, and immigrant status. Family disposable income at the year of recorded diagnosis was used as a proxy for income and was treated as a dichotomous variable (i.e., lowest tertile versus middle and top tertiles). For the 2 developmental disorders (ADHD and autism), as the patients were relatively young, with nearly half lacking income data, we used the disposable income data of their parents. Single status was defined according to the year of diagnosis, and referred to individuals who were unmarried, divorced, or widowed. Immigrant status was defined as being born outside of Sweden.

Statistical analyses {#sec013}
--------------------

We designed the analytic strategy when the study was conceived including the exposures (main psychiatric diagnoses), outcome (arrests for IPV), and statistical approach (Cox regression). For each patient, up to 20 general population controls without the studied mental disorders were matched by age (birth year) and sex. We adopted Cox regression to control for time to event, and to account for the potential impact of death as a competing event for arrest for IPV. In the current study, the rate of death during follow-up was higher among men with psychiatric diagnoses (1.6% to 7.1%) than among their matched general population controls (0.4% to 1.1%). Cox regression showed that, compared to general population controls, men with mental disorders were 3 to 11 times more likely to die during the follow-up. Thus, in our Cox regression, instead of omitting people who died during follow-up from the survival analyses, we treated "failure" from death as a censored observation, while "failure" from the outcome of interest (i.e., IPV) as an event. We report results from the Cox regression, with mental disorders as the predictor, and IPV against women after the diagnosis of a mental disorder as the outcome. We included family disposable income, single status, and immigrant status as confounders. Missing data are minimal in this study: less than 10% for income and 3% for single status across comparisons. No other data were missing.

To account for possible confounding by familial factors, we conducted additional analyses with unaffected, sex-matched full siblings of patients as controls. Unaffected full siblings were siblings without a diagnosis of the examined disorder but not necessarily without other mental disorders. For instance, when investigating the link between depression and IPV, the sibling comparisons were siblings without a diagnosis of depression but with or without substance use disorders or other psychiatric disorders. We compared unaffected full siblings of the patients with 20 age- and sex-matched general population controls with Cox regression. As in the models comparing patients and general population controls, we controlled for family disposable income, single status, and immigrant status and calculated hazard ratios of IPV against women for unaffected siblings of individuals with mental disorders.

Then, we compared the hazard ratios obtained in patient analyses to those obtained in sibling analyses using the ratio of hazard ratios (RHR). The RHR provides one way of accounting for familial factors including genetic and early family environmental factors. An RHR of 1 indicates that the risk of IPV against women in those with mental disorders is the same as the risk in their unaffected full siblings. That is, if there is an association between a mental disorder and IPV in the primary analysis, but the RHR is 1, then the association between the mental disorder and IPV is fully confounded by genetic and environmental factors shared by full siblings.

We conducted several additional sensitivity analyses. First, we compared the risk of arrest for IPV between psychiatric patients with and without comorbidity of alcohol use disorder, drug use disorder, or personality disorders, as these disorders are often comorbid with other psychiatric disorders and are associated with antisocial behaviors \[[@pmed.1002995.ref034]--[@pmed.1002995.ref037]\]. In addition, we conducted interaction analyses between mental disorders and comorbidity of these 3 disorders to further examine differences between groups in the Cox regression model. Second, to investigate confounding by substance use disorders, we adjusted associations between mental disorders and IPV for substance use disorders prior to the exposure. Third, we performed subgroup analysis by inpatient and outpatient diagnosis to examine group differences. Fourth, we examined the association between mental disorders and arrest for general domestic violence to examine whether mental disorders were associated with IPV against women and with general domestic violence in a similar pattern in men. Fifth, to mitigate against reverse causality (because IPV might precipitate diagnoses of mental disorders), we ran separate analyses in a subgroup of individuals without a record of IPV before their diagnosis with a mental disorder. We used R statistical software in our analyses.

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([S1 Checklist](#pmed.1002995.s001){ref-type="supplementary-material"}).

Results {#sec014}
=======

Descriptive findings {#sec015}
--------------------

We examined the risk of IPV against women by men in 9 diagnostic groups, with sample sizes ranging from 9,529 individuals with autism to 88,182 persons with depressive disorder. The average age at the beginning of follow-up (the year of receiving a diagnosis between 1998 and 2013) was 18 years for autism, 23 years for ADHD, and 30--34 years for the other mental disorders. Other characteristics are reported in Tables [1](#pmed.1002995.t001){ref-type="table"} and [S1](#pmed.1002995.s002){ref-type="supplementary-material"}. The mean duration of follow-up across diagnoses ranged from 3.4 years to 4.8 years. The absolute rate of IPV perpetrated by men towards women ranged from 0.1% in individuals with autism to 2.1% in those with drug use disorder, from 0.2% to 0.8% among unaffected siblings, and from 0.1% to 0.4% in the matched general population controls ([Table 2](#pmed.1002995.t002){ref-type="table"}).

10.1371/journal.pmed.1002995.t001

###### Descriptive data for men with mental disorders, unaffected full siblings, and matched general population controls.

![](pmed.1002995.t001){#pmed.1002995.t001g}

  Mental disorder                    Characteristic        Individuals with mental disorders[^a^](#t001fn002){ref-type="table-fn"}   General population controls   Unaffected full siblings
  ---------------------------------- --------------------- ------------------------------------------------------------------------- ----------------------------- --------------------------
  Schizophrenia-spectrum disorders   Sample size           26,085                                                                    518,801                       11,592
                                     Follow-up start age   32.7 (9.1)                                                                32.7 (9.1)                    31.0 (9.5)
                                     Low income            17,152 (67.3%)                                                            150,569 (30.0%)               3,975 (36.5%)
                                     Single status         23,337 (90.8%)                                                            370,983 (73.3%)               9,085 (79.6%)
                                     Born abroad           6,623 (25.4%)                                                             63,579 (12.3%)                1,263 (10.9%)
                                     Previous IPV          372 (1.4%)                                                                1,776 (0.3%)                  62 (0.5%)
  Bipolar disorder                   Sample size           12,065                                                                    239,388                       5,758
                                     Follow-up start age   34.2 (10.2)                                                               34.1 (10.2)                   33.0 (10.2)
                                     Low income            6,203 (53.2%)                                                             64,863 (28.6%)                1,777 (32.7%)
                                     Single status         9,696 (81.2%)                                                             166,445 (71.5%)               4,230 (75.0%)
                                     Born abroad           1,436 (11.9%)                                                             27,875 (11.6%)                230 (4.0%)
                                     Previous IPV          198 (1.6%)                                                                1,224 (0.5%)                  25 (0.4%)
  Depressive disorder                Sample size           88,182                                                                    1,719,318                     36,453
                                     Follow-up start age   31.7 (10.8)                                                               31.7 (10.8)                   30.7 (10.9)
                                     Low income            41,344 (49.2%)                                                            447,487 (27.8%)               10,424 (31.2%)
                                     Single status         72,276 (82.6%)                                                            1,266,415 (75.7%)             28,006 (77.9%)
                                     Born abroad           15,142 (17.2%)                                                            186,326 (10.8%                2,066 (5.7%)
                                     Previous IPV          1,334 (1.5%)                                                              6,631 (0.4%)                  165 (0.5%)
  Anxiety disorder                   Sample size           60,355                                                                    1,195,303                     28,962
                                     Follow-up start age   30.3 (11.1)                                                               30.3 (11.1)                   29.5 (10.7)
                                     Low income            24,459 (44.2%)                                                            311,913 (29.0%)               8,417 (32.2%)
                                     Single status         49,790 (83.0%)                                                            909,608 (78.2%)               22,906 (80.2%)
                                     Born abroad           8,167 (13.5%)                                                             124,450 (10.4%)               1,985 (6.9%)
                                     Previous IPV          790 (1.3%)                                                                4,583 (0.4%)                  134 (0.5%)
  Alcohol use disorder               Sample size           82,731                                                                    1,643,539                     37,885
                                     Follow-up start age   31.1 (11.2)                                                               31.0 (11.2)                   29.4 (11.2)
                                     Low income            40,172 (51.3%)                                                            405,390 (26.4%)               10,431 (30.9%)
                                     Single status         73,707 (89.9%)                                                            1,226,776 (76.5%)             30,531 (81.5%)
                                     Born abroad           10,080 (12.2%)                                                            184,520 (11.2%)               2,251 (5.9%)
                                     Previous IPV          1,744 (2.1%)                                                              4,743 (0.3%)                  149 (0.4%)
  Drug use disorder                  Sample size           57,901                                                                    1,151,306                     24,116
                                     Follow-up start age   30.6 (10.3)                                                               30.5 (10.3)                   29.6 (10.5)
                                     Low income            33,745 (59.9%)                                                            334,162 (30.1%)               7,845 (35.3%)
                                     Single status         51,976 (91.0%)                                                            883,380 (78.6%)               19,463 (81.8%)
                                     Born abroad           9,783 (16.9%)                                                             126,675 (11.0%)               2,302 (9.5%)
                                     Previous IPV          1,360 (2.3%)                                                              3,440 (0.3%)                  117 (0.5%)
  ADHD                               Sample size           49,327                                                                    976,123                       22,576
                                     Follow-up start age   23.3 (11.5)                                                               23.3 (11.4)                   24.1 (11.2)
                                     Low income            20,212 (45.5%)                                                            234,967 (26.9%)               6,603 (31.6%)
                                     Single status         46,321 (94.2%)                                                            839,175 (88.1%)               19,795 (88.7%)
                                     Born abroad           3,923 (8.0%)                                                              70,768 (7.3%)                 965 (4.3%)
                                     Previous IPV          804 (1.6%)                                                                2,635 (0.3%)                  96 (0.4%)
  Autism                             Sample size           9,529                                                                     186,017                       4,818
                                     Follow-up start age   17.7 (10.4)                                                               18.0 (10.3)                   19.6 (10.3)
                                     Low income            3,116 (39.5%)                                                             41,453 (26.6%)                1,255 (30.1%)
                                     Single status         9,432 (99.3%)                                                             171,504 (94.0%)               4,501 (94.2%)
                                     Born abroad           796 (8.4%)                                                                10,838 (5.8%)                 261 (5.4%)
                                     Previous IPV          18 (0.2%)                                                                 271 (0.1%)                    9 (0.2%)
  Personality disorders              Sample size           19,850                                                                    394,367                       9,128
                                     Follow-up start age   33.4 (8.8)                                                                33.4 (8.8)                    31.9 (9.5)
                                     Low income            13,941 (71.2%)                                                            117,542 (30.7%)               3,313 (38.0%)
                                     Single status         17,740 (90.4%)                                                            279,429 (72.8%)               7,100 (78.9%)
                                     Born abroad           3,336 (16.8%)                                                             48,081 (12.2%)                688 (7.5%)
                                     Previous IPV          647 (3.3%)                                                                1,606 (0.4%)                  62 (0.7%)

Values are given as *n* (%), except for follow-up start age, which is given as mean (standard deviation).

^a^Including all patients with or without unaffected full siblings.

ADHD, attention deficit hyperactivity disorder; IPV, intimate partner violence.

10.1371/journal.pmed.1002995.t002

###### Risks of IPV against women in men with mental disorders and their unaffected siblings compared to general population controls, and also in men with mental disorders compared to their unaffected siblings (as ratio of adjusted hazard ratios \[RHR\]).

![](pmed.1002995.t002){#pmed.1002995.t002g}

  Mental disorder                    Individuals with mental disorders who perpetrated IPV   Unaffected full siblings who perpetrated IPV   RHR         CI      *p-*Value                                                                                                                          
  ---------------------------------- ------------------------------------------------------- ---------------------------------------------- ----------- ------- ----------- ---------- ----- ---------- --------- ------------ ------ ----- ---------- ----- ---------- --------- ----- ---------- ---------
  Schizophrenia-spectrum disorders   209 (0.8%)                                              0.4%                                           4.0 (3.1)   4.6%    1.9         1.7--2.2   1.5   1.3--1.7   \<0.001   93 (0.8%)    0.3%   2.7   2.2--3.4   2.2   1.8--2.7   \<0.001   0.7   0.5--0.9   0.002
  Bipolar disorder                   60 (0.5%)                                               0.3%                                           3.4 (3.0)   3.1%    2.2         1.7--2.8   2.2   1.7--2.8   \<0.001   13 (0.2%)    0.2%   1.3   0.7--2.3   1.2   0.6--2.2   0.600     1.8   0.9--3.7   0.088
  Depressive disorder                705 (0.8%)                                              0.2%                                           3.7 (2.9)   12.8%   3.3         3.1--3.6   2.9   2.7--3.2   \<0.001   73 (0.2%)    0.2%   1.3   1.1--1.7   1.2   0.9--1.5   0.150     2.4   1.9--3.2   \<0.001
  Anxiety disorder                   362 (0.6%)                                              0.2%                                           3.7 (3.0)   8.8%    2.5         2.3--2.8   2.5   2.2--2.7   \<0.001   87 (0.3%)    0.2%   1.7   1.4--2.2   1.5   1.2--1.9   \<0.001   1.7   1.3--2.1   \<0.001
  Alcohol use disorder               1,406 (1.7%)                                            0.3%                                           4.6 (3.4)   18.3%   6.1         5.8--6.5   7.0   6.6--7.5   \<0.001   152 (0.4%)   0.2%   1.7   1.4--2.0   1.6   1.4--1.9   \<0.001   4.4   3.7--5.2   \<0.001
  Drug use disorder                  1,216 (2.1%)                                            0.3%                                           4.7 (3.4)   22.3%   7.2         6.7--7.7   7.7   7.2--8.3   \<0.001   121 (0.5%)   0.2%   2.4   2.0--2.9   2.1   1.7--2.5   \<0.001   3.7   3.0--4.5   0.028
  ADHD                               296 (0.6%)                                              0.1%                                           3.8 (3.2)   19.4%   5.1         4.5--5.7   6.4   5.5--7.4   \<0.001   45 (0.2%)    0.1%   2.1   1.5--2.8   2.1   1.5--2.8   \<0.001   3.1   2.2--4.3   \<0.001
  Autism                             10 (0.1%)                                               0.1%                                           4.8 (3.3)   0.2%    0.5         0.2--1.2   0.7   0.3--1.6   0.380     10 (0.2%)    0.1%   2.1   1.2--3.9   2.2   1.2--3.9   0.010     0.3   0.1--0.9   \<0.001
  Personality disorders              337 (1.7%)                                              0.4%                                           4.4 (3.3)   13.5%   4.8         4.3--5.4   4.3   3.8--4.9   \<0.001   64 (0.7%)    0.2%   3.0   2.3--3.9   2.5   1.9--3.3   \<0.001   1.7   1.3--2.3   \<0.001

Each individual with a mental disorder and his unaffected full sibling were compared with 20 age- and sex-matched general population controls. Adjusted hazard ratio analyses were adjusted for family income, single status, and immigrant status.

ADHD, attention deficit hyperactivity disorder; aHR, adjusted hazard ratio; cHR, crude hazard ratio (not adjusted for any covariates); CI, confidence interval; IPV, intimate partner violence; PAR (%), population attributable risk percent; SD, standard deviation.

Main results {#sec016}
------------

When compared with general population controls ([Table 2](#pmed.1002995.t002){ref-type="table"}), all psychiatric diagnoses except autism were associated with an increased risk of IPV against women by men, with hazard ratios ranging from 1.5 (95% CI 1.3--1.7) to 7.7 (95% CI 7.2--8.3) (*p-*values \< 0.001). Analyses comparing hazard ratios in patients (versus population controls) and unaffected siblings (versus population controls) showed that men with depressive disorder, anxiety disorder, alcohol use disorder, drug use disorder, ADHD, and personality disorders had higher risk of IPV against women than their unaffected full siblings, with RHR values ranging from 1.7 (95% CI 1.3--2.1) to 4.4 (95% CI 3.7--5.2) (*p-*values \< 0.001) ([Table 2](#pmed.1002995.t002){ref-type="table"}; [Fig 1](#pmed.1002995.g001){ref-type="fig"}). When comparing the hazard ratios from patient analyses to those from the sibling analyses, individuals with schizophrenia-spectrum disorders (RHR = 0.7 \[95% CI 0.5--0.9\], *p* = 0.002) and autism (RHR = 0.3 \[95% CI 0.1--0.9\], *p* \< 0.001) had lower risks of IPV perpetration against women than their unaffected siblings. The covariates in the models were associated with IPV perpetration. Hazard ratios ranged from 1.7 to 2.4 for low (lowest tertile) family income, 1.2 to 2.1 for single status (except for in models testing the association of schizophrenia-spectrum disorders and bipolar disorder with IPV), and 3.5 to 6.4 for immigrant status across models ([S2 Table](#pmed.1002995.s003){ref-type="supplementary-material"}).

![Ratio of hazard ratios (men with mental disorders versus siblings) of intimate partner violence against women.\
The ratio of hazard ratios is the hazard ratio for individuals with mental disorders versus 20 age- and sex-matched general population controls divided by the hazard ratio for unaffected siblings versus 20 age- and sex-matched general population controls. The bars represent the 95% confidence intervals. ADHD, attention deficit hyperactivity disorder.](pmed.1002995.g001){#pmed.1002995.g001}

Sensitivity analyses {#sec017}
--------------------

We conducted additional analyses by subgroups with and without comorbidity of alcohol use disorder, drug use disorder, and personality disorders (Tables [3](#pmed.1002995.t003){ref-type="table"} and [S3](#pmed.1002995.s004){ref-type="supplementary-material"}). We found that the hazard ratio of IPV against women for men with mental disorders was increased with comorbid substance use disorders and personality disorders (except in autism). These group differences were supported by interaction effects between mental disorders (except for autism) and comorbidity (all *p-*values \< 0.001, except for *p* = 0.004 for the interaction between schizophrenia-spectrum disorders and drug use disorder).

10.1371/journal.pmed.1002995.t003

###### Hazard ratio of intimate partner violence against women in men with mental disorders by psychiatric comorbidity.

![](pmed.1002995.t003){#pmed.1002995.t003g}

  Mental disorder                    Comorbidity of alcohol use disorder   Comorbidity of drug use disorder   Comorbidity of personality disorder                                                                                                                                                                                          
  ---------------------------------- ------------------------------------- ---------------------------------- ------------------------------------- --------- -------- ----- ---------- --------- -------- ------ ----------- --------- -------- ----- ---------- --------- ------- ------ ----------- --------- -------- ----- ---------- ---------
  Schizophrenia-spectrum disorders   5,525                                 3.1                                2.4--3.9                              \<0.001   20,560   1.1   0.9--1.3   0.340     7,171    3.3    2.6--4.1    \<0.001   18,914   0.9   0.8--1.1   0.540     4,424   3.4    2.6--4.4    \<0.001   21,661   1.1   0.9--1.3   0.330
  Bipolar disorder                   2,960                                 5.2                                3.5--7.6                              \<0.001   9,105    1.3   0.9--1.8   0.200     2,543    5.3    3.4--8.2    \<0.001   9,522    1.5   1.1--2.1   0.021     1,825   4.8    2.7--8.6    \<0.001   10,240   1.9   1.4--2.5   \<0.001
  Depressive disorder                16,174                                7.3                                6.4--8.5                              \<0.001   72,008   1.9   1.7--2.1   \<0.001   13,397   6.6    5.6--7.7    \<0.001   74,785   2.2   2.0--2.4   \<0.001   7,437   4.9    4.0--6.0    \<0.001   80,745   2.7   2.4--2.9   \<0.001
  Anxiety disorder                   7,962                                 7.6                                6.1--9.4                              \<0.001   52,393   1.7   1.5--2.0   \<0.001   7,463    8.5    6.9--10.4   \<0.001   52,892   1.6   1.4--1.9   \<0.001   2,920   4.4    3.2--6.1    \<0.001   57,435   2.3   2.0--2.6   \<0.001
  Alcohol use disorder                                                                                                                                                                            21,275   10.4   9.3--11.5   \<0.001   61,456   5.6   5.1--6.1   \<0.001   6,125   11.2   9.3--13.5   \<0.001   76,606   6.6   6.2--7.1   \<0.001
  Drug use disorder                  21,334                                11.1                               9.9--12.3                             \<0.001   36,567   5.6   5.1--6.2   \<0.001                                                                             7,220   11.1   9.5--13.0   \<0.001   50,681   7.0   6.5--7.6   \<0.001
  ADHD                               8,527                                 12.6                               9.8--16.3                             \<0.001   40,800   4.5   3.8--5.5   \<0.001   10,791   11.3   9.1--14.1   \<0.001   38,536   4.2   3.4--5.1   \<0.001   4,391   12.5   9.2--17.0   \<0.001   44,936   5.2   4.4--6.2   \<0.001
  Autism                             419                                   8.1                                2.0--32.6                             0.003     9,110    0.4   0.1--1.2   0.085     421      7.3    1.5--36.0   0.014     9,108    0.3   0.1--1.1   0.081     364     3.3    0.5--20.7   0.200     9,165    0.5   0.2--1.4   0.170
  Personality disorders              6,144                                 6.7                                5.5--8.3                              \<0.001   13,706   3.1   2.6--3.7   \<0.001   7,221    6.4    5.3--7.7    \<0.001   12,629   2.8   2.3--3.5   \<0.001                                                                  

Each individual with a mental disorder was compared with 20 age- and sex-matched general population controls. aHR analyses were adjusted for family income, single status, and immigrant status.

ADHD, attention deficit hyperactivity disorder; aHR, adjusted hazard ratio; CI, confidence interval.

We conducted analyses with general domestic violence perpetrated by men as the outcome ([S4 Table](#pmed.1002995.s005){ref-type="supplementary-material"}), and found that mental disorders were similarly associated with general domestic violence. Hazard ratios ranged from 1.6 (95% CI 1.4--1.9) to 7.0 (95% CI 6.6--7.5) (*p-*values \< 0.001) when comparing individuals with mental disorders to population controls; substance use disorders showed the highest hazard ratios (HRs \> 6.2, *p-*values \< 0.001). Comparisons with hazard ratios in unaffected full siblings (versus general population controls) also showed similar patterns, with RHRs ranging from 1.4 (95% CI 1.1--1.8) to 3.7 (95% CI 3.0--4.4) (*p-*values \< 0.001).

In addition, individuals with an inpatient psychiatric diagnosis in general showed a higher hazard ratio than those with an outpatient diagnosis, particularly for depressive, anxiety, and drug use disorders ([S5 Table](#pmed.1002995.s006){ref-type="supplementary-material"}).

Furthermore, we conducted a series of other sensitivity analyses. In one set of analyses, we removed individuals with a history of IPV, and in another we adjusted for alcohol and drug use disorders prior to a psychiatric diagnosis. We also tested models without adjusting for any covariates. All of these analyses did not materially change the hazard ratios of IPV perpetration among men with mental disorders (Tables [2](#pmed.1002995.t002){ref-type="table"}, [S6](#pmed.1002995.s007){ref-type="supplementary-material"} and [S7](#pmed.1002995.s008){ref-type="supplementary-material"}).

Discussion {#sec018}
==========

We examined the risk of IPV against women perpetrated by men with 9 psychiatric diagnoses in a Swedish population-based study over 1998--2013. The sample sizes of diagnostic groups ranged from 9,529 individuals (with autism) to 88,182 (with depressive disorder). When compared to the general population, we found that men with mental disorders, apart from those with autism, were more likely to perpetrate IPV against women. These associations remained after adjustment for familial confounding, apart from the low-prevalence disorders (likely due to lack of statistical power to show differences). Men with alcohol and drug use disorders had the highest risks (7- to 8-fold increased risks) compared with general population controls, and those with ADHD and personality disorders were also consistently at an increased risk across models. Furthermore, the comorbidity of substance use disorders and personality disorders increased the risk of IPV against women in men with all investigated psychiatric diagnoses.

Our findings underscore that substance use disorders are the primary diagnoses with the highest relative risk among all studied disorders for the risk of IPV perpetration, and that substance use disorder comorbidity increases the risk of IPV perpetration for other mental disorders. Alcohol and drug use disorders decrease an individual's inhibition, which in turn can lead to the use of violence to solve conflicts in intimate relationships \[[@pmed.1002995.ref038]\]. People with mental disorders are also likely to use alcohol and drugs as coping strategies to deal with difficult symptoms associated with their illnesses \[[@pmed.1002995.ref039],[@pmed.1002995.ref040]\]. Therefore, alcohol and drug use disorders could be underlying mechanisms linking other mental disorders to later IPV perpetration, in addition to being strong independent predictors themselves. Overall, our findings suggest that prevention and intervention programs should prioritize assessment of risk of IPV in men with diagnosis of substance use disorders, especially because these disorders are treatable \[[@pmed.1002995.ref041]\].

Furthermore, the comorbidity of substance use disorders was associated with a substantially increased risk of IPV perpetration in all the other mental disorders, including autism, which did not show a higher risk on its own compared to general population controls. These results could help reduce the stigma around IPV perpetration in mental disorders in general, as IPV risk was much lower without comorbidity of substance use disorders. In addition, the findings provide an important preventative target for clinicians working in adult mental health services, who may not be including risk to intimate partners as part of their risk assessments nor focusing on the risk patients may pose in the context of drug and alcohol misuse (which is more common in individuals with mental disorders than in the general population) \[[@pmed.1002995.ref042]\].

We found that schizophrenia-spectrum disorders showed higher risk of IPV perpetration than general population controls. However, individuals with these disorders did not show higher risk than their unaffected full siblings, although this may reflect low statistical power. This result, although needing further replication, contrasts with those from studies reporting links between schizophrenia-spectrum disorders and general violence \[[@pmed.1002995.ref043]\]. In addition, research that showed an association between psychosis and domestic homicides also reported that perpetrators with symptoms at the time of offense were less likely than perpetrators without symptoms to have previous violence convictions \[[@pmed.1002995.ref044]\]. It is possible that common symptoms of schizophrenia-spectrum disorders such as paranoid ideation are associated with general violence but not necessarily with violence against intimate partners \[[@pmed.1002995.ref045]\].

It is important to note that the results for autism and schizophrenia-spectrum disorders were different. That is, autism was associated with a lower risk of IPV both in the general population comparisons and sibling comparisons. However, schizophrenia-spectrum disorders were associated with a higher risk of IPV in the general population comparisons but not in the sibling analyses. Familial factors might explain this association. It is possible that unaffected siblings may not have a clinical diagnosis of a schizophrenia-spectrum disorder but may still have underlying cognitive impairments, which may lead to IPV in both affected and unaffected full siblings. Moreover, it could be that individuals with autism are less likely to have intimate partners and thus have less opportunity for violence against partners. In addition, those who have partners might present with less severe symptoms of autism.

We found a higher risk of IPV perpetration among individuals with an inpatient diagnosis than with an outpatient diagnosis for 3 psychiatric diagnoses (depressive, anxiety, and drug use disorders). This suggests that the links between these mental disorders and IPV might function in a dose--response pattern, as inpatients can be assumed to have more severe underlying disorders.

Low income was associated with IPV perpetrated by men towards women. This finding is consistent with existing research on the link between financial distress and increased IPV \[[@pmed.1002995.ref046]\]. In addition, men who were not married were more likely to commit IPV against women. This could mean that, on average, marriage implies a more stable and committed relationship than unmarried partnership, and thus is associated with reduced IPV risks. Furthermore, we found that immigrant status (being born outside of Sweden) was associated with a higher risk of IPV against women, which may be explained by cultural differences \[[@pmed.1002995.ref002]\].

Overall, we have shown that mental disorders, particularly substance use disorders, personality disorders, and ADHD, are associated with an increased risk of IPV perpetration. Therefore, treatment of these disorders could potentially reduce the risk in these groups, especially as evidence-based interventions exist \[[@pmed.1002995.ref047]--[@pmed.1002995.ref050]\]. For example, it has been reported that among ADHD patients receiving medication, a significant reduction of criminality rate is observed \[[@pmed.1002995.ref051]\]. Furthermore, integrated interventions for mental disorders and IPV may be particularly helpful. This approach is supported by a randomized controlled trial of cognitive behavioral therapy that reduced both the symptoms of substance use disorders and IPV among male offenders \[[@pmed.1002995.ref052]\].

Although our study is observational and causality cannot be inferred, if causality was assumed, then population attributable risk percentages could be interpreted as the maximum possible impact that fully treating a disorder would have on IPV---these ranged from 0.2% for autism to 22.3% for drug use disorders. Treating substance misuse, common deficits such as affect regulation, and specific symptoms of mental disorders might be an important step to prevent IPV against women in some men with psychiatric diagnoses. These findings also suggest that to reduce men's IPV against women, other modifiable risk factors in addition to mental disorders need to be considered. More specifically, other individual risk factors of men's IPV against women include comorbidity of substance use disorders, as showed in this study, and stressful life events, such as previous victimization and witnessing domestic violence during childhood \[[@pmed.1002995.ref053],[@pmed.1002995.ref054]\]. Apart from developmental history and current characteristics of individuals, the WHO ecological framework highlights that environmental factors including gender disadvantage (e.g., in education and employment), structural factors, and characteristics of the relationship could also contribute to IPV against women \[[@pmed.1002995.ref001],[@pmed.1002995.ref055],[@pmed.1002995.ref056]\]. It is currently unclear how factors at the individual level interact with associations at the relationship, community, and societal levels. Future research is necessary to clarify this.

Our findings also highlight the need for examining underlying mechanisms. In addition to providing treatment for common deficits and specific core symptoms of mental disorders, it is important to examine factors at the relationship level. It is likely that individuals with mental disorders selectively end up in abusive intimate partnerships, which could lead to reactive violence towards partners \[[@pmed.1002995.ref057]\]. Moreover, there has been evidence of assortative mating (or non-random mating) within and across major mental disorders such as substance use disorders, schizophrenia, depression, and ADHD \[[@pmed.1002995.ref058]\], which might increase the risk of IPV perpetration due to cognitive and social impairments in both partners. Empirical studies are needed to examine potential mediators linking mental disorders to IPV perpetration.

Our study has several strengths. First, we used a longitudinal research design, which accounts for the temporal sequence between mental disorders and IPV perpetration. Second, we tested the associations between mental disorders and IPV perpetration in a population-based sample, which increases the generalizability of the findings. In addition, using arrest for IPV as the outcome means that the findings may be more reliable, as self-report may be more prone to cultural biases \[[@pmed.1002995.ref059]\]. Third, although we cannot demonstrate a causal relationship, the criminal coding in the National Crime Register enabled us to retrieve data on this specific type of violent perpetration in men, which is not recorded separately in many other countries. Furthermore, using arrest data from this national register enabled analyses with sufficient statistical power to study these associations more precisely than previous work, and the arrest data could be linked accurately with healthcare and family registers---a comparable interview-based study would be very large and expensive, and may not be possible (especially in finding and interviewing siblings). The Multi-Generation Register allowed us to conduct full sibling comparisons to control for shared familial factors that might contribute to both mental disorders and IPV perpetration \[[@pmed.1002995.ref027]\]. Fourth, we also conducted a series of sensitivity analyses, such as analyses removing individuals with a history of IPV, subgroup analyses of persons with comorbidity of substance use disorders and personality disorders, and analyses adjusting for alcohol and drug use disorders prior to a psychiatric diagnosis. We found no material differences in hazard ratios between results from these sensitivity analyses and those from the main analyses. These complementary methods enabled us to provide more precision in estimating the link between mental disorders and IPV. These strengths help overcome limitations of prior studies based on selected samples \[[@pmed.1002995.ref060]\].

Several limitations should be noted. First, we used arrest for IPV as the outcome. The absolute rate of IPV perpetration arrests ranged from 0.1% in men with autism to 2.1% in men with alcohol use disorder over an average follow-up of 3.4 to 4.8 years. As it has been widely recognized that victims of partner abuse tend to not report the abuse to the police, and many men might have already perpetrated IPV prior to the age of 15 years (the age of inclusion in the crime register), not all IPV is captured by this approach \[[@pmed.1002995.ref061]\], and our findings are specific to more severe forms of IPV perpetration that lead to arrest and likely have significant negative consequences for victims, such as serious morbidity and in rare cases mortality. However, other research has shown that the degree of underreporting of violence is similar for violence perpetrated by patient groups and by the general population \[[@pmed.1002995.ref062]\]. Therefore, even though we only captured a subset of IPV perpetrations, the relative risk estimates in the patient analyses (patients versus general population controls) and sibling analyses (siblings versus general population controls) should not be significantly affected. Second, there could be a selection bias against individuals who are in a vulnerable position, such as those with low socioeconomic status being more likely to be arrested for IPV \[[@pmed.1002995.ref063]\]. This may have inflated the prevalence of IPV among certain diagnostic groups. The risk estimates therefore might be overestimated, although our adjustment for income, use of sibling comparisons, and sensitivity analyses excluding individuals arrested for IPV before diagnosis most likely mitigated this potential bias. Third, our exposure was psychiatric diagnosis. As many individuals with a mental disorder do not get a formal diagnosis, our patients represent the more severe cases (but those who are accessing services). For example, in this study, individuals with substance use disorders were those with a diagnosis recorded in official patient registries. Most people with a substance use disorder might never get a diagnosis. Thus, our sample represented a group of people with more severe substance use problems but with the advantage that they are accessing services and therefore can be further assessed and treated. Fourth, as some of the disorders investigated were relatively rare (schizophrenia-spectrum disorders, bipolar disorders), the sibling comparisons were likely underpowered to demonstrate differences. Fifth, previous studies have suggested that borderline and antisocial personality disorders are more likely to be associated with IPV than dependent personality disorders \[[@pmed.1002995.ref064]\]. However, due to lack of data on the diagnostic validity of specific personality disorders, we did not investigate links between individual personality disorders and IPV. Finally, the study was done in one country. However, as the prevalences of IPV against women (23.2% in Sweden versus 25.4% in Europe overall) and mental disorders in Sweden are similar to those in other high-income countries \[[@pmed.1002995.ref065]--[@pmed.1002995.ref069]\], our findings are likely generalizable to other high-income countries.

Conclusions {#sec019}
-----------

In summary, we examined the link between mental disorders and later IPV using a large population-based cohort of male IPV perpetrators and, to our knowledge for the first time, compared the risks in men with mental disorders to those in unaffected siblings, to account for genetic and family environmental factors. Our results suggest longitudinal associations between many mental disorders, particularly substance use disorders, ADHD, and personality disorders, and IPV against women by men. Substance use disorders as a primary diagnosis were associated with the highest risk of IPV perpetration among the studied psychiatric diagnoses, and comorbid substance use disorders were associated with an increased likelihood of IPV perpetration in all of the other disorders examined. Our findings suggest that prioritizing the development of services to assess IPV perpetration among men with substance use disorders may help to reduce the risk of IPV against women.
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4\. Abstract: Methods and findings: Please quantify the main results (with 95% CIs and p values).
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9\. Introduction (and Abstract): Please define the abbreviation "ADHD" at the instance of first use.

10\. Methods and Results: Please provide the actual numbers of events for the outcomes, not just the absolute rates. Specifically, provide the actual numbers associated with the rates of IPV for each population (Table 2 data). It is not clear where the absolute rates of IPV are provided for the population controls. Please specify in the first paragraph of the results section where these results are presented.
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16\. Discussion: Please revise the following sentence: "Furthermore, as the comorbidity of substance use disorders substantially increased the risk of IPV perpetration in all the other mental disorders, including autism which did not show a higher risk when compared to general population controls, these findings could help reducing the stigma around IPV perpetration in mental disorders in general as their higher risk is largely due to substance use disorders."

Specifically, your study is observational and therefore causality cannot be inferred. Please remove language that implies causality, such as "\...as their higher risk is largely due to substance use disorders." This statement implies causality. Refer to associations instead.

17\. Discussion/Conclusion: Please avoid assertions of primacy (\"We report for the first time\....\") and greatest size. Specifically, please revise the following sentence: "In summary, we examined the link between mental disorders and later IPV using the largest sample of IPV perpetrators and for the first time compared to risks in unaffected siblings to account for genetic and family environmental factors."

18\. Discussion/Conclusion: The statement "\...and comorbid substance use disorders increased the risk of IPV against women in all of the other disorders examined..." implies causality. Your study is observational and therefore causality cannot be inferred. Please revise and refer to associations instead.

19\. Table 2, Table 3, Figure 1, Appendices 1,3, 4, and 5: Please define the abbreviation "CI" in the legend.

20\. All Tables and Figures: Please define the abbreviation "ADHD" in the legend.

21\. Table 1, and Appendix 2: Please clarify which variables are N (%) and which variables are mean (SD).

22\. Please ensure that the study is reported according to the STROBE guideline, and include the completed STROBE checklist as Supporting Information. When completing the checklist, please use section and paragraph numbers, rather than page numbers. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\"

Comments from the reviewers:

Reviewer \#1: This is a well-conducted study on the associations between mental disorders and men\'s intimate partner violence against women using population data. The study design, datasets, statistical methods and analyses, presentation (tables and figures) and interpretation of results are mostly adequate and of a good standard. However, still a few statistical issues needing attention.

1\) In the statistical analyses of the Methods section, it says \'We compared patients\' unaffected full siblings with 20 age and gender- matched general population controls with matched conditional logistic

regression\'. What does this mean and what is it for? We have some odd ratios here but never appeared anywhere in the paper as only Hazard Ratios were applied throughout the paper.

2\) Competing risk. Cox models were applied in the paper to assess the risks, and the outcome is the men\'s IPV against women other than all-cause mortality, therefore death could be a competing risk in the survival analysis. Can authors elaborate what the death rates are in these cohort? What\'s its impact on survival analysis in terms of competing risk?

3\) As all the cox models were adjusted for potential confounders, we would like to see the influence/impact of these confounders in the analyses, such as the impact of family income, single status, and immigrant status. We didn\'t see these confounders presented and discussed in the results or discussion sections.

Reviewer \#2: This is a very good and relevant paper

Reviewer \#3: The authors examine the association between ICD-9 mental disorders and official arrests for IPV in a very large Swedish population cohort. Results indicate that the presence of almost any disorder increases risk for IPV arrests, with substance use disorders and ADHD having the strongest associations with IPV outcomes.

There are many positives to this important paper. The manuscript is efficiently written and very well-organized. The statistical approach is excellent, and the manner with which they address important confounding variables is a notable strength. The results are clearly presented, and conclusions are closely aligned with their findings. The paper truly stands apart from comparable studies that have been published regarding the mental illness-IPV link in terms of sample, data analysis/statistical controls, presentation of findings, and overall quality.

If there is one area that is below the generally high quality seen in the overall paper and is in need of further narrative attention, it is the authors\' discussion of the etiological links between mental illness and IPV (including the role of substance use in IPV perpetration). There was no discussion of how or why mental illness might be linked to IPV in the Introduction, and the authors\' coverage of this topic in the Discussion was severely lacking in breadth and depth. This is an exceedingly important issue in the IPV field in particular, as large sections of the field steadfastly refuse to acknowledge the role of mental illness in any form (e.g., personality traits, specific diagnoses, even alcohol use) as being causally related to IPV perpetration. This resistance, often rooted in protofeminist models of patriarchal socialization, consider such factors as excuses rather than the actual causes of IPV, which are presumed to be rooted in acceptance of personal responsibility. The main point is that there should be no a priori presumption that a large section of readers of this article will accept the very idea of this research, much less the actual findings. Therefore, more careful attention needs to be paid to specific etiological models of how, why, and which mental illnesses are connected to IPV perpetration. While there are a few sentences devoted to some potential mechanisms on p. 14, the authors state that (a) emotion regulation might be involved in emotion disorders (of course); (b) that the psychoactive properties of alcohol might relate to aggression (of course); and (c) that two subtypes of IPV might be important considerations (even though the subtype construct has largely fallen out of scientific favor). The authors are encouraged to be more mindful in their discussion of relevant theory and to more conscientiously discuss the actual and potential mechanisms associated with these models that link mental disorder to IPV perpetration.

Any attachments provided with reviews can be seen via the following link:
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28 Oct 2019

Dear Dr. Fazel,

Thank you very much for re-submitting your manuscript \"Mental disorders and intimate partner violence perpetrated by men towards women: a population-based longitudinal study\" (PMEDICINE-D-19-02530R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by 2 reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Nov 04 2019 11:59PM.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

1.Title: Please revise the title to: "Mental disorders and intimate partner violence perpetrated by men towards women: a Swedish population-based longitudinal study"

2.Data Availability: Thank you for providing the weblink to request access to the individual level data. However, this link goes to a very general page. If you can provide a more specific location or contact information where readers can request access to the data, that would be helpful.

3.Abstract: Background: In the final sentence, please avoid any misleading implications that the sibling comparison controlled for all genetic and family environmental factors. We suggest removing the word "all" from the sentence.

4.Abstract: Methods and Findings: Please include the years during which the study took place, and the length of follow up.

5\. Abstract: Methods and Findings: Please revise the final sentence to: "A limitation of our study is that our analysis was restricted to instances of IPV leading to arrest, suggesting that these results may be applicable to more severe forms of IPV perpetration." or similar.

6\. Abstract: Conclusions: Please revise the first sentence to: Our results indicate that some mental disorders are associated with an increased risk of perpetrating IPV towards women, and that substance use disorders, as principal or comorbid diagnoses, have the highest relative and absolute risks." or similar.

7\. Abstract: Conclusions: Please revise the final sentence to: These findings support the idea that developing services for the assessment of IPV perpetration risk among men with substance use disorders could help to reduce the prevalence of IPV." or similar.

8\. Author Summary: Please use bullet points to denote separate items here.

9\. Author Summary: "Why was this study done?": Please remove "substantial" and "wide" from the first point, as they do not convey specific meaning.

10\. Author Summary: Why was this study done?: The second and third points could be combined, for example: "Mental disorders are associated with increased risk of IPV perpetration; however, the nature and strength of the associations are uncertain because of limitations in study design and confounding factors in previous studies." Or similar.

11\. Author Summary: What did the researchers do and find?: We suggest combining the first and second points, for example: "We calculated the relative risk of IPV against women in men with psychiatric disorders identified in a Swedish population-based sample, and also compared the risk of perpetrating IPV in men with psychiatric disorders with their unaffected siblings." or similar.

12\. Author Summary: What did the researchers do and find?: For the second point, we suggest: "Most of the studied mental disorders were associated with a higher risk of IPV against women; the absolute rate of IPV against women ranged from 0.1% for autism and 2.1% for drug use disorders. Associated risks were two to seven times compared with the general population and two to four-fold compared with their unaffected siblings." or similar.

13\. Author Summary: What do these findings mean?: Please revise the first point to: "We found that several mental disorders are associated with increased risk of IPV against women, and the risk is further increased when there is a comorbidity with substance misuse."

14\. Introduction: 2nd paragraph: Please revise the second sentence to read: "Common deficits associated with mental disorders, such as impaired interpersonal skills and emotional dysregulation, and specific core symptoms of certain disorders, such as impulsivity manifested in individuals with ADHD and substance use disorders, and hostility exhibited in some people with mood disorders and antisocial personality disorder (9-12), have been linked to IPV against women (13, 14)." or similar. Also, please specifically reference your supporting literature for statements of "poor interpersonal skills", "emotional dysregulation", "impulsivity manifested in ADHD and substance use disorders", and "hostility exhibited in some people with mood disorders and antisocial personality disorders".

15\. Introduction: 2nd paragraph: These two sentences seem to be saying essentially the same thing, please revise accordingly to consolidate: "Preliminary evidence suggests that individuals with mental illness have increased risk of IPV against women. A higher prevalence of IPV perpetration has been found in individuals with mental disorders than those without." Please also provide references for this.

16\. Introduction: 3rd paragraph: Please revise the abbreviation to "\...Attention Deficit Hyperactivity Disorder (ADHD)\..." Also, please spell out the definition of this term at its first instance, in paragraph 2 rather than in this paragraph.

17\. Introduction: Final paragraph: Please revise the second sentence of this paragraph to: "To this end, we investigated the incidence of IPV in men with various mental disorders in a population-based sample using a longitudinal design." or similar.

18\. Methods: Outcome measure: Please revise the final sentence of this paragraph to: "The primary outcome was first IPV arrest after diagnosis." or similar.

19\. Results: Descriptives: Please show the absolute rates of IPV perpetrated by men towards women for the matched general population controls (as in Table 2 for the unaffected sibling data, or as a separate table) and refer to this in the text.

20\. Results: Thank you for your response to Reviewer 1, Point R1.3. However, can you please also provide the complete set of hazard ratios for the confounders, (e.g. presented in a table).

21\. Discussion: 2nd paragraph: Please revise the first sentence of this paragraph to: "Our findings underscore that risk of IPV in those with substance use disorders as the primary diagnosis had the highest risk among all studied disorders, and that substance use disorder comorbidity increased the risk of IPV for other disorders." or similar.

22\. Discussion: 3rd paragraph: Please provide a reference to support the final sentence: "This might be particularly helpful\...focusing on the risk patients may pose in the context of drug and alcohol (which are more commonly used by individuals with mental disorders than the general population."

23\. Discussion: Page 17: Please revise the first sentence of this paragraph to: "Overall, we have shown that mental disorders, particularly substance use disorders, personality disorders, and ADHD, are associated with risk of IPV perpetration." or similar.

24\. Discussion: Page 18: Please revise the first sentence of this paragraph to: "Although our study is observational and causality cannot be inferred, if causality were to be assumed, then population risk percentages can be interpreted as..." or similar to avoid the implication of a causal relationship.

25\. Discussion: Page 18: Please provide a reference for the statement: "It is likely that individuals with mental disorders selectively end up in abusive intimate partnerships, which could lead to reactive violence towards partners."

26\. Discussion: Conclusions: Please revise the final sentence to: "Our findings suggest that prioritizing the development of services to assess IPV perpetration among men with substance use disorders may help to reduce the risk of IPV against women." or similar.

27\. Figure 1: Please include in the legend that the bars represent the 95% confidence intervals, rather than indicating this on the y-axis label.

28\. Table 3: There are no RHR values presented, although the title indicates that there are.

29\. Table 3, Appendix 1, 3, 4 and 5: Please present unadjusted (crude) hazard ratios in addition to the adjusted results.

30\. Appendix 5 Table: Please indicate in the legend that ratio of hazard ratios (RHRs) are presented.

Comments from Reviewers:

Reviewer \#1: Thanks authors for their effort to improve the manuscript. I am satisfied with the response and the revision. No further issues needing attention.

Reviewer \#3: In the context of my review of the original submission, the present version of the authors\' manuscript is improved substantially. There is more careful attention paid to the narrative surrounding the theoretical factors that may account for the association between mental disorder and IPV, and the overall discussion is more in line with current theory and research in this area. Overall, this is a strong paper that is likely to make a significant impact on our understanding of IPV perpetration risk and in the development of novel prevention programs.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1002995.r004
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18 Nov 2019

Dear Dr. Fazel,

On behalf of my colleagues and the academic editor, Dr. Phillipa Hay, I am delighted to inform you that your manuscript entitled \"Mental disorders and intimate partner violence perpetrated by men towards women: a Swedish population-based longitudinal study\" (PMEDICINE-D-19-02530R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: AJNH is funded by Johnson and Johnson and received funds from Ono Pharma in 2018. HL has served as a speaker for Evolan Pharma and Shire and has received research grants from Shire; all outside the submitted work. LMH is the lead investigator on a UK Research and Innovation funded Mental Health Network on Violence, Abuse and Mental Health.
